EGFR and plasma cell myeloma: reported that SP myeloma cells are more resistant to bortezomib or melphalan chemotherapy and that SP abundance and clonogenicity are regulated by the activated-leukocyte-cell-adhesion-molecule (ALCAM)/EGFR-EGF signaling axis (49, 51).